Eugene William St. Clair, MD

Professor of Medicine
W. Lester Brooks, Jr. Professor of Medicine
Chief, Division of Rheumatology and Immunology
Professor in Immunology
Campus mail 34229 Hosp South, Durham, NC 27710
Phone (919) 684-4499
Email address stcla003@mc.duke.edu

The main focus of my research is the pathogenesis and treatment of rheumatoid arthritis (RA). This work has been conducted using patient-oriented research methodologies in collaboration with basic scientists and other clinical investigators. A major area of interest has been the development of novel therapies for RA, which has primarily included studies of novel biologics. Another important area of investigation has been the possible role of nitric oxide in the pathogenesis of RA.

My research is conducted in our Clinical Trials Unit which is built around a staff of three clinical research coordinators and a collaborative relationship with Dr. William E. Wilkinson, a Ph.D. biostatistician. Our group has been involved in numerous clinical trials sponsored by the pharmaceutical industry. Another important project has been a study of doxycycline therapy in RA, which has been supported by the National Institutes of Health (NIH). Recently, we have
begun an epidemiologic study of SLE in collaboration with Glinda Cooper, an epidemiologist from the National Institutes of Environmental Health Services in the Research Triangle Park. The General Clinical Research Center, an NIH-supported facility, has frequently served as the site for our research.

The current biologic therapies under investigation in patients with RA include a peptide vaccine, IL-4, IL-10, and anti-tumor necrosis factor-à chimeric monoclonal antibody (anti-TNF). The peptide vaccine consists of a "shared HLA-DRB1 epitope", a short amino acid sequence common to the -chain of those HLA-DR molecules associated with RA. IL-4 and IL-10 are inhibitory cytokines that ameliorate arthritis in experimental animal models and are in the early stages of development as a possible treatment for human disease. The most promising of the novel biologics are those agents inhibiting TNF. Our center is now involved in a phase III clinical trial of anti-TNF in patients with RA, a study involving over 20 other sites in the United States and Europe. I am also principal investigator of an NIH-sponsored study investigating the treatment efficacy of doxycycline in RA and the ability of this antibiotic to suppress collagenase activity in vivo. The work involving nitric oxide has been supported by a Specialized Center for Research in RA (Barton F. Haynes, M. D., Principal Investigator). Other current studies include a clinical trial of DHEA in SLE, and the epidemiologic study of SLE, which is based in North and South Carolina and will examine the relationship between environmental exposures and the incidence of disease.

I have been a consultant for several pharmaceutical companies who are developing new therapies for RA. In addition, I have served as a consultant on NIH study sections for applications related to clinical trials of new anti-rheumatic therapies. I have also organized a Sjogren's Syndrome Clinic at Duke that attracts referrals from the southeastern part of the United States. I have also spoken at the Annual Scientific Meeting of the American College of
Rheumatology on subjects related to my research and clinical interests, including Sjogren's Syndrome, vasculitis, and autoantibodies. Finally, I am developing an investigator's network in the southeastern United States, which should provide the patient base and infrastructure to conduct large clinical trials in rheumatology.

Key words: rheumatoid arthritis, biologics, clinical trials, Sjogren's syndrome, systemic lupus erythematosus, nitric oxide

Education and Training

  • Chief Resident, Medicine, Duke University, 1984 - 1985
  • Fellow in Rheumatology, Medicine, Duke University, 1983 - 1985
  • Medical Resident, Medicine, Duke University, 1980 - 1983
  • M.D., West Virginia University, 1980

Publications

Shiboski, Caroline H., Stephen C. Shiboski, Raphaèle Seror, Lindsey A. Criswell, Marc Labetoulle, Thomas M. Lietman, Astrid Rasmussen, et al. “2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts..” Arthritis Rheumatol 69, no. 1 (January 2017): 35–45. https://doi.org/10.1002/art.39859.

PMID
27785888
Full Text

Geetha, Duvuru, Sanjeev Sethi, An S. De Vriese, Ulrich Specks, Cees G. M. Kallenberg, Noha Lim, Robert Spiera, et al. “Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis..” Am J Nephrol 46, no. 3 (2017): 231–38. https://doi.org/10.1159/000480443.

PMID
28881339
Full Text

Miloslavsky, Eli M., Na Lu, Sebastian Unizony, Hyon K. Choi, Peter A. Merkel, Philip Seo, Robert Spiera, et al. “Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets..” Arthritis Rheumatol 68, no. 12 (December 2016): 2945–52. https://doi.org/10.1002/art.39812.

PMID
27428559
Full Text

Wampler Muskardin, Theresa, Priyanka Vashisht, Jessica M. Dorschner, Mark A. Jensen, Beverly S. Chrabot, Marlena Kern, Jeffrey R. Curtis, et al. “Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis..” Ann Rheum Dis 75, no. 10 (October 2016): 1757–62. https://doi.org/10.1136/annrheumdis-2015-208001.

PMID
26546586
Full Text

Ormseth, Michelle J., Patricia G. Yancey, Joseph F. Solus, S Louis Bridges, Jeffrey R. Curtis, MacRae F. Linton, Sergio Fazio, et al. “Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis..” Arthritis Rheumatol 68, no. 9 (September 2016): 2099–2105. https://doi.org/10.1002/art.39675.

PMID
26991245
Full Text

Mills, John R., Divi Cornec, Surendra Dasari, Paula M. Ladwig, Amber M. Hummel, Melissa Cheu, David L. Murray, et al. “Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis..” Anal Chem 88, no. 12 (June 21, 2016): 6317–25. https://doi.org/10.1021/acs.analchem.6b00544.

PMID
27228216
Full Text

Unizony, Sebastian, Miguel Villarreal, Eli M. Miloslavsky, Na Lu, Peter A. Merkel, Robert Spiera, Philip Seo, et al. “Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type..” Ann Rheum Dis 75, no. 6 (June 2016): 1166–69. https://doi.org/10.1136/annrheumdis-2015-208073.

PMID
26621483
Full Text

McCallum, R. M., E. W. St.Clair, and B. F. Haynes. “Cogan's syndrome.” In Inflammatory Diseases of Blood Vessels, 491–509, 2016.

Scholars@Duke

St Clair, E William. “ACR Presidential Address: RethinkingRheumatology: A Brave New World..” Arthritis Rheumatol 68, no. 2 (February 2016): 277–81. https://doi.org/10.1002/art.39533.

PMID
26636263
Full Text

Taylor, William J., and E William St Clair. “Editorial: Shifting the Goal Posts: Treatment Recommendations for Ankylosing Spondylitis and the Newly Defined Condition of Nonradiographic Axial Spondyloarthritis..” Arthritis Rheumatol 68, no. 2 (February 2016): 265–69. https://doi.org/10.1002/art.39300.

PMID
26407084
Full Text

Pages